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The presence of olfactory dysfunction in individuals at higher risk of Alzheimer’s disease has signiﬁcant diagnostic and screening
implications for preventive and ameliorative drug trials. Olfactory threshold, discrimination and identiﬁcation can be reliably
recorded in the early stages of neurodegenerative diseases. The current study has examined the ability of various olfactory
functions in predicting cognitive decline in a community-dwelling sample. A group of 308 participants, aged 46–86 years old, were
recruited for this study. After 3 years of follow-up, participants were divided into cognitively declined and non-declined groups
based on their performance on a neuropsychological battery. Assessment of olfactory functions using the Snifﬁn’ Sticks battery
indicated that, contrary to previous ﬁndings, olfactory discrimination, but not olfactory identiﬁcation, signiﬁcantly predicted
subsequent cognitive decline (odds ratio¼0.869; Po0.05; 95% conﬁdence interval¼0.764 0.988). The current study ﬁndings
conﬁrm previously reported associations between olfactory and cognitive functions, and indicate that impairment in olfactory
discrimination can predict future cognitive decline. These ﬁndings further our current understanding of the association between
cognition and olfaction, and support olfactory assessment in screening those at higher risk of dementia.
Translational Psychiatry (2012) 2, e118; doi:10.1038/tp.2012.43; published online 22 May 2012
Introduction
Olfactory dysfunction has been reliably demonstrated in
Alzheimer’sdisease(AD)
1–3andmildcognitiveimpairment.
4,5
Of note, olfactory impairment has also been reported in
cognitively healthy individuals positive for apolipoprotein E e4
(APOE-e4)allele,themaingeneticriskfactorforAD,
6,7aswell
as in those with another potential risk factor for AD, namely
subjective memory complaints.
8
Indeed, olfactory dysfunction has been signiﬁcantly asso-
ciatedwiththeriskoffutureADandADneuropathologyburden
in the brain.
9 AD-related neuropathological studies of animals
and humans have indicated the following: (i) A negative
associationbetweenamyloid-beta(b-amyloid)loadinthebrain
and olfaction;
10–12 (ii) A strong association between tau
pathology in olfactory system, Braak staging of AD pathology
and cognitive decline;
13,14 and (iii) Presence of oxidative
damage in the olfactory epithelium in the early stages of
AD.
15,16
Observational and clinical studies have found a signiﬁcant
association between olfactory impairment and subsequent
cognitivedecline.Forexample,alarge-scalestudy(N¼1920)
on the relationship between olfactory identiﬁcation ability and
general cognitive functioning (as measured by Mini Mental
State Examination (MMSE)) indicated that olfactory dysfunc-
tion at baseline was signiﬁcantly predictive of future cognitive
impairment after 5 years (odds ratio (OR)¼6.62; conﬁdence
interval (CI)¼4.36–10.04).
17 Schubert et al.
17 have also
reported low sensitivity of 55.1% but high speciﬁcity (84.4%)
for olfactory assessment in predicting cognitive decline.
However, the olfaction/cognition relationship has not been
consistently found, particularly when more complicated
olfactory assessment instruments including electrophysiolo-
gical measures were used in addition to psychophysical
methods.
18 Indeed, the different methods utilized to assess
olfaction may be responsible for the inconsistent ﬁndings.
19
Olfactory abilities are primarily assessed by measuring
threshold (lowest detectable concentration of odors), discri-
mination (ability to differentiate between odors) and identiﬁca-
tion (ability to identify odors).
20 It has been suggested that
olfactory threshold is strongly related to sensory capability,
while olfactory discrimination and identiﬁcation are more
closely associated with higher cognitive functions, and thus
may be more cognitively loaded.
8,21 A dated, but still
informative,reviewhasreportedastrongassociationbetween
cognitive functions and certain aspects of olfactory function-
ing, concluding that compared with the ability to detect odors,
identiﬁcation of odors is more challenging, perhaps due to a
lack of access to verbal or visual representations of odors.
22
Similarly, Schab
23 noted that odor identiﬁcation may repre-
sent a semantic memory function. Some researchers suggest
that olfactory identiﬁcation is primarily predictive of memory
decline.
24 It is interesting that while verbal and visual cues
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ories usually last longer than memories formed through other
sensory modalities and have more emotional valence.
25,26
There is strong evidence that neuroanatomical regions
involved in episodic memory, including the medial temporal
lobe, are also associated with olfactory functioning.
27,28
Interestingly, individuals with hippocampal lesions show
signiﬁcantly poorer olfactory recognition compared with odor
threshold.
29
Olfactory impairment is not conﬁned to people with AD or
AD-related cognitive decline, and it has been reported in
individuals suffering from other neurodegenerative diseases
such as Parkinson’s disease, frontotemporal dementia and
Lewy body dementia.
30–32 Olfactory deﬁcits have also been
reported in psychiatric disorders including schizophrenia and
depression.
33,34 As such, olfactory dysfunctions appear not to
be speciﬁc to AD.
35,36 Further studies are needed to improve
the sensitivity and speciﬁcity of olfactory screening to identify
which olfactory domains are speciﬁcally affected at particular
stages of preclinical AD.
We hypothesized that olfactory ability at baseline could
predict altered cognitive function in a 3-year follow-up
assessment. The speciﬁc questions examined by the current
study were the following: (1) Is there any association between
olfaction and cognition at baseline in this cohort of apparently
healthy aging individuals? (2) Could baseline olfactory
function predict future (3-year) cognitive decline? (3) Which
olfactory domain(s) best predict cognitive alteration?
Materials and methods
Design. Participants were derived from a larger, longitudinal
study, ‘the Western Australia Memory Study’ (for more
information on this cohort, see refs 8,37–39). Participants
were monitored for 3 years, and underwent annual neuro-
psychological, biochemical and physiological examinations.
Herein, the baseline and ﬁnal assessment (two-point data)
results of this study will be examined. The study was
approved by the Human Research Ethics Committees of
the associated institutions, namely the University of Western
Australia, Edith Cowan University and Hollywood Private
Hospital. Participants provided informed consent before
baseline assessments according to the guidelines of the
National Health and Medical Research Council of Australia.
Participants. A total of 308 community-dwelling older adults
aged 46–86 years old (68% female) were recruited from a
larger study cohort. The volunteers’ family members were
also invited to participate. The APOE-e4 genotype was
available for 273 participants, of whom 34% were e4 allele
carriers (e2-e4, e3-e4, or e4-e4). The mean education level for
the cohort was 13.5 years (±3.77), and inclusion criteria
were a minimum of 6 years of education, age 45 and over,
and ﬂuency in English. Exclusion criteria for this study
included: (i) a baseline score of p24 in MMSE
40 and p81 in
the Cambridge Cognitive Examination-Revised (CAMCOG-
R);
41 (ii) history of anosmia or any known olfactory problems;
and (iii) history or formal diagnosis of medical, neurological
or psychiatric diseases and disorders affecting olfactory
capacities (for example, sinunasal diseases, upper respira-
tory tract infection, severe head injury, Parkinson’s disease,
schizophrenia, and so on).
Measures. Olfactory function was assessed using the
‘Extended Snifﬁn’ Sticks’ battery (Burghart, Wedel, Ger-
many), in which odors are presented using felt-tip pen-like
sticks.
42 The Extended Snifﬁn’ Sticks assess three domains of
olfactory function, using threshold (T), discrimination (D) and
identiﬁcation (I) as three subscales and enabling calculation of
a composite score, namely TDI.
43,44 In this study, the Snifﬁn’
Sticks battery was administered in a triple forced-choice
staircase method as outlined previously
45 and also in the test
manual (Burghart).
The CAMCOG-R
46 and MMSE
40 were used to assess
general cognitive functioning. The CAMCOG-R measures
orientation, language, memory, attention, abstract thinking,
praxis and calculation abilities, and provides a total score of
cognitive functioning. The MMSE is commonly used as a
screening measure to assess general cognitive performance
in clinical and research settings.
47
APOE genotyping. Blood samples were collected into
different blood collection tubes including serum, EDTA
(containing prostaglandin E) and heparin (Interpath Services,
West VIC, Australia). The DNA was isolated from leukocytes,
and APOE genotype was determined using PCR ampliﬁcation
and restriction enzyme digestion as previously described.
48,49
Statistical analysis. All statistical analyses were performed
using PASW Statistics 18 for Windows 7. Partial correlation
was applied to control for the effects of age. Variables
examined in this study including sex, APOE genotype, age at
baseline, baseline cognitive function and olfactory
performance, as measured by Snifﬁn’ Sticks, were entered
in a logistic regression model using the enter analysis model.
After the completion of 3-year follow-up, participants were
divided into two groups: cognitively declined and non-
declined. Participants were considered to be ‘cognitively
declined’ if their score on the ﬁnal cognitive assessment (as
measured by CAMCOG-R) was X1 s.d. below their baseline
performance.
Results
Cohort demographics. For this study, 308 participants with
a mean age of 63.06 (±7.25) years undertook neuropsycho-
logical testing. Demographic characteristics of the cohort are
shown in Table 1. The scores of male/female and APOE-e4
carrier and non-carrier groups on the MMSE, Snifﬁn’ Sticks
and CAMCOG-R at baseline (Table 1) were all above the
cutoff scores, as required in the exclusion criteria (40,41,50,
respectively).
Mackay-Sim et al.
51 provide guidelines for the classiﬁcation
of differing levels of olfactory impairment using Snifﬁn’ Sticks:
(1) severe hyposmia (a score of p23 on Snifﬁn’ Sticks TDI for
women and p21 for men); (2) anosmia (a TDI score of p16);
and(3)mildhyposmia(inwomenascoreof23–27,andinmen
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Translational Psychiatrya score of 21–29). In our cohort, 6.5, 1.3 and 19.5% met these
criteria, respectively.
In this cohort, 194 (62.98) participants were non-smokers,
105 (34.09) were ex-smokers (with at least 2 years of
abstinence) and9 (2.93) participantswere smokers.However,
as there were no signiﬁcant differences between the non-
smokers and other groups in any of the baseline assessments
including age, education, cognitive function (as assessed by
MMSE and CAMCOG-R) and olfactory assessments, we did
not include smoking as a factor in this study.
Cognitive performance over time. There was no
signiﬁcant association between sex and cognitive decline
(w
2
(1)¼0.179, P¼0.672) or APOE genotypes and cognitive
decline (w
2
(1)¼1.773, P¼0.183). Participants who were
classiﬁed as declined (n¼58) performed more poorly on
olfactory discrimination (t¼3.14; df¼286; Po0.05) and on
cumulative olfactory performance (t¼1.33; df¼306; Po.05)
as measured by Snifﬁn’ Sticks TDI (Table 2). The declined
group was older at baseline as compared with non-declined
group (N¼250; t¼ 2.39; df¼306; Po0.05), but did not
differ on other demographic variables including education
and cognitive functioning as measured by MMSE and
CAMCOG-R.
Analysis of the association between the variables indicated
thatagewasnegativelyassociatedwithbaselineCAMCOG-R
(r¼ 0.171; Po0.01), Snifﬁn’ Sticks T (r¼ 0.193; Po0.01),
D( r¼ 0.260; Po0.01), I (r¼ 0.188; Po0.01) and TDI
(r¼ 0.296; Po0.01). The CAMCOG-R was signiﬁcantly
associatedwithbaselineSnifﬁn’SticksD(r¼0.253;Po0.01),
I( r¼0.271; Po0.01) and TDI (r¼0.228; Po0.01), but not
with Snifﬁn’ Sticks T (r¼ 0.006; Po0.92). To control the
effects of age on the associations between various variables,
partial correlation was performed. Partial correlation analysis
indicated that even after controlling for the effects of age,
baseline CAMCOG-R was still signiﬁcantly associated with
Table 1 Baseline descriptive results (age, years of education, cognitive measures and olfactory function were assessed and data analyzed in terms of gender and
APOE genotype; Total N¼308)
Variables Male
(N¼99)
Female
(N¼209)
P APOE-e4
a
non-carrier (N¼202)
APOE-e4 carrier
(N¼99)
P Total cohort
Age 65.19 (±7.59) 62.05 (±6.88) 0.000* 63.43 (±7.62) 62.70 (±6.39) 0.413 63.06 (±7.25)
Education years 14.05 (±4.14) 13.34 (±3.56) 0.127 13.58 (±3.91) 13.41 (±3.43) 0.713 13.57 (±3.77)
MMSE 29.05 (±1.12) 29.20 (±1.09) 0.281 29.16 (±1.17) 29.11 (±0.96) 0.729 29.15 (±1.10)
CAMCOG-R 98.58 (±3.58) 98.71 (±3.34) 0.743 98.75 (±3.50) 98.49 (±3.12) 0.536 98.67 (±3.41)
SS-T 7.03 (±2.58) 7.58 (± 2.34) 0.063 7.44 (±2.35) 7.30 (±2.09) 0.622 7.40 (±2.37)
SS-D 11.31 (±2.25) 11.88 (±2.43) 0.058 11.83 (±2.37) 11.49 (±2.41) 0.260 11.69 (±2.39)
SS-I 12.64 (±1.80) 12.49 (±2.04) 0.539 12.54 (±1.98) 12.56 (±1.80) 0.919 12.54 (±1.96)
SS-TDI 30.67 (±4.53) 31.72 (±4.63) 0.061 31.54 (±4.58) 31.08 (±4.53) 0.414 31.38 (±4.62)
Abbreviations: CAMCOG-R, The Revised Cambridge Cognitive Examination; MMSE, Mini Mental State Examination; SS-D, Snifﬁn’ Sticks discrimination; SS-I,
Snifﬁn’ Sticks identiﬁcation; SS-T, Snifﬁn’ Sticks threshold; SS-TDI, Snifﬁn’ Sticks composite score.
aApolipoprotein E e4 allele. *Pp0.05.
Table 2 Demographic information and baseline performance of cognitively declined
a and non-declined participants
Variables Age Educ. years
b MMSE CAMCOG-R SS-T SS-D SS-I SS-TDI
Non-declined
(N¼250)
62.59 (±6.98) 13.65 (±3.65) 29.20 (±1.11) 98.63 (±3.28) 7.53 (±2.32) 11.90 (±2.21) 12.62 (±1.91) 31.79 (±4.13)
Declined
(N¼58)
65.10 (±8.08) 13.22 (±4.25) 28.95 (±1.05) 98.84 (±3. 94) 6.87 (±2.55) 10.80 (±2.86) 12.20 (±2.16) 29.65 (±6.04)
P 0.017* 0.442 0.124 0.664 0.063 0.009*
,c
0.153 0.013*
,c
Abbreviations: CAMCOG-R, The Revised Cambridge Cognitive Examination; MMSE, Mini Mental State Examination; SS-D, Snifﬁn’ Sticks discrimination; SS-I,
Snifﬁn’ Sticks identiﬁcation; SS-T, Snifﬁn’ Sticks threshold; SS-TDI, Snifﬁn’ Sticks composite score.
aCognitive decline was considered as a score X1 s.d. below baseline performance on CAMCOG-R in the last assessment.
bEducation years.
cEqual variance not
assumed. *Pp0.05.
Table 3 Prediction of cognitive decline
a using Snifﬁn’ Sticks discrimination in multiple logistic regression analysis (N¼282)
b
Factors B s.e. Wald df P* OR 95% CI for OR
Lower Upper
Sex  0.005 0.340 0.000 1 0.988 0.995 0.511 1.937
APOE genotypes  0.518 0.323 2.579 1 0.108 0.596 0.316 1.121
Age at baseline 0.031 0.023 1.846 1 0.174 1.035 0.986 1.078
Education years  0.008 0.042 0.039 1 0.843 0.992 0.912 1.078
MMSE  0.140 0.132 1.119 1 0.290 0.870 0.617 1.127
SS-D  0.141 0.066 4.582 1 0.032* 0.869 0.764 0.988
Abbreviations: CAMCOG-R, The Revised Cambridge Cognitive Examination; CI, conﬁdence interval; MMSE, Mini Mental State Examination; OR, odds ratio; SS-D,
Snifﬁn’ Sticks discrimination.
aCognitive decline was considered as a score X1 s.d. below baseline performance on the CAMCOG-R in the last assessment.
bN was 308; however, only 282 were
entered in the actual analysis. *Po 0.05.
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Translational PsychiatrySnifﬁn’SticksD (r¼0.296,Po0.01),I(r¼0.218,Po0.01)and
TDI (r¼0.277, Po0.01). The association between baseline
olfactory functions with cognitive decline after 3 years was
further explored using logistic regression analysis (Tables 3
and4).The ‘D’scalewassigniﬁcantlyassociatedwithcognitive
decline (OR¼0.869; Po0.05; 95% CI¼0.764 0.988); how-
ever, neither ‘T’ (OR¼0.916; Po0.192; 95% CI¼0.803–
1.045) nor ‘I’ (OR¼0.917; Po0.262; 95% CI¼0.787–1.067)
was signiﬁcantly associated with cognitive decline as deﬁned
by CAMCOG-R performance in the last assessment (Table 3).
Interestingly, baseline cognitive function (as measured by
CAMCOG-R) and olfactory abilities showed similar trend of
decline(Figure1). However, other factorsincluding sex, APOE
genotype, age at baseline and baseline MMSE score were not
signiﬁcantly associated with cognitive decline in this study.
Logistic regression analysis indicated that higher Snifﬁn’
Sticks TDI (composite) score was associated with lower risk of
cognitivedecline(OR¼0.872;Po0.05;95%CI¼0.872 0.992)
(Table 4). Other variables, including sex, APOE genotype, age,
education and baseline MMSE score, did not indicate a
signiﬁcant predictive value with regards to cognitive decline.
Discussion
The major novel ﬁnding of the current study was that olfactory
discrimination (as measured by Snifﬁn’ Sticks D) was a
signiﬁcant predictor of future cognitive decline over a 3-year
period. The study also conﬁrmed a series of existing ﬁndings,
demonstrating that age is associated with both cognitive and
olfactory functions. However, there was a signiﬁcant associa-
tion between olfactory function and cognitive performance
even after controlling for the effects of age, education years,
APOE genotype and sex. Three olfactory functions including
threshold, discrimination and identiﬁcation were separately
assessed in this study. Interestingly, we found that discrimi-
nation was the best predictor of cognitive decline over time. It
is important to note that the cognitive changes observed were
small and subtle with the study participants performing within
the normal range on cognitive measures.
Interestingly, our ﬁndings do not support those of other
researchers who have reported that impaired olfactory identi-
ﬁcation is a strong predictor of cognitive impairment.
52–55
Wilson et al.
56 further reported that impairment in olfactory
identiﬁcation at baseline was signiﬁcantly associated with the
incidence of mild cognitive impairment. It has been reported
that patients who were anosmic at baseline had twice the risk
of developing AD compared with controls over a 2-year follow
up, and if they had at least one APOE-e4 allele, the risk
increased to 4.9 times.
7 It should be noted that while some
researchers report a signiﬁcant olfactory decline in individuals
positive for APOE-e4 allele,
6 others have failed to ﬁnd this
relationship
8,57 and our current ﬁndings are consistent with
these latter studies.
The reports on olfactory identiﬁcation impairments in AD
patients and in individuals at higher risk for pathological
cognitive decline are not conclusive. That is, impairment in
both olfactory identiﬁcation and threshold have been reported
as predictive of cognitive decline and AD.
52,55,58,59 One
potential explanation is odor discrimination is primarily
impaired in AD individuals while identiﬁcation problems are
Table 4 Predictors of cognitive decline
a using Snifﬁn’ Sticks total, composite score in multiple logistic regression analysis (N¼282)
b
Factors B s.e. Wald df P* OR 95% CI for OR
Lower Lower
Sex 0.095 0.333 0.082 1 0.775 1.100 0.572 2.113
APOE genotypes  0.442 0.316 1.964 1 0.161 0.642 0.346 1.193
Age at baseline 0.034 0.022 2.296 1 0.130 1.035 0.990 1.081
Education years  0.008 0.042 0.035 1 0.851 0.992 0.914 1.077
MMSE  0.158 0.130 1.482 1 0.223 0.852 0.663 1.101
SS-TDI  0.073 0.033 4.842 1 0.028* 0.930 0.872 0.992
Abbreviations:CAMCOG-R,TheRevisedCambridgeCognitiveExamination;CI,conﬁdenceinterval;MMSE,MiniMentalStateExamination;OR,oddsratio;SS-TDI,
Snifﬁn’ Sticks composite score.
aCognitive decline was considered as a score X1 s.d. below baseline performance on the CAMCOG-R in the last assessment.
bN was 308; however, only 282 were
entered in the actual analysis. *Po0.05.
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Figure 1 Dual axes graph showing the association between age, the
CAMCOG-R and the Snifﬁn’ Sticks composite score.
J The Cambridge Cognitive
Examination-Revised (CAMCOG-R) total score; *Snifﬁn’ Sticks TDI (composite
score). The dual axes graph with linear trend lines shows the baseline performance
on cognitive measure (CAMCOG-R total score) and general olfactory function (as
derived from the Snifﬁn’ Sticks composite score). Both the CAMCOG-R (upper line)
and SS TDI (below the ﬁrst line) linear lines show a close trend of decline over time.
The mean scores were used for this graph.
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Translational Psychiatrymore common among patients with semantic dementia,
frontotemporal dementia or corticobasal dementia.
60 Another
explanation for our ﬁndings is that previous studies have
focused primarily, often exclusively, on odor identiﬁcation and
might have not extensively assessed other olfactory domains
including threshold and discrimination.
61,62 It has been
suggested that olfactory discrimination, similar to identiﬁca-
tion, requires higher cognitive functions including working
memory, judgment and decision making, and its dysfunction
may represent generalized cognitive deterioration.
63 Our
ﬁndings support this interpretation. However, involvement of
hippocampal regions in a network underlying odor discrimina-
tion
64 increases the probability of a more speciﬁc memory-
related role in discrimination. Clearly, more studies are
needed to clarify the neural regions associated with
odor discrimination and cognition. As demonstrated in the
present study, controlled, systematic evaluation of the
various olfactory domains would contribute to more power-
ful assessment of the cognitive elements of odor memory
and recognition, and thus also possible links to cognitive
function.
The association of age with both cognitive
65 and olfactory
25
functions is consistent with the reports indicating that age is a
signiﬁcant covariate. However, the ﬁndings reported in this
study indicate that the association between cognitive func-
tions and olfactory discrimination and identiﬁcation is inde-
pendent of the effects of age. It has been argued that the
effects of age on olfaction can be explained by the effects of
cognitive decline, not age or age-related hazards affecting
olfaction.
66 Age, per se, may not account for the so-called
age-associated olfactory dysfunction or presbyosmia, as
decline in olfactory function with healthy aging seems much
lower than previously reported.
67 Given this, our ﬁndings
support previous reports suggesting that cognitive functions,
speciﬁcally those with higher verbal component, are signiﬁ-
cantly associated with olfaction.
66,68
Another signiﬁcant ﬁnding was the value of measuring
multiple domains of olfactory functioning in predicting cogni-
tive decline over 3 years in community-dwelling elderly
individuals. Previous reports have mainly focused on the
value of measuring speciﬁc olfactory domains such as
identiﬁcation in predicting pathological or age-related cogni-
tive decline (for examples, see refs 17,56,69). The study
reported here indicated that a comprehensive measure of
olfactory function has signiﬁcant power in predicting cognitive
decline in healthy individuals. As various olfactory functions
are to some degree reliant on threshold,
70 it is necessary to
assess the participants’ olfactory acuity before further
assessment with more specialized measures such as
identiﬁcation
71 thatmay then beused fordifferential diagnosis
or screening purposes.
The mechanisms underlying the association between
olfaction and cognition have been extensively examined in
the last 100 years both by psychophysics and neuroanatomi-
cal studies (72,73, for a review of earlier work see Herz and
Engen
74). For example, psychophysics studies have found
that olfactory identiﬁcation was signiﬁcantly associated with
semantic verbal memory, implying that the two may share
some cognitive domains.
66,75–77 Neuropathological studies
have revealed that brain regions and subsystems involved in
odor information processing, including the olfactory bulb,
piriform and orbital prefrontal cortices, have direct projections
to perirhinal and entorinal cortices. These, in turn, have
extensive projections to the hippocampus,
78–80 known as the
primary brain region involved in initial memory formation,
81–83
and also one of the ﬁrst regions affected in AD neurodegen-
eration.
84,85 In addition, the anterior olfactory nucleus and
olfactory bulb are the two primary brain regions commonly
affected in AD.
86,87 Indeed, change in olfactory identiﬁcation
has been strongly associated with pathological changes in the
medial temporal lobe structures.
88 These studies strongly
imply a primary role for olfactory dysfunction as an indicator of
pathological cognitive decline and dementia.
The current study had some limitations that should be
considered when interpreting the ﬁndings reported. First,
participants were both physically and cognitively within the
normal range, at least as far as it can be inferred from the
MMSE, CAMCOG-R, years of education and various exclu-
sion criteria applied during the participants recruitment phase.
In addition, the participants were divided into declined/non-
declined groups based on neuropsychological measures and
not a formal diagnostic clinical interview. However, the
CAMCOG-R is a comprehensive measure of cognitive func-
tion, and while it cannot be considered as a substitute for
formal clinical evaluation of the participants, it has demon-
strated high sensitivity to cognitive decline.
89,90 Ideally, any
future research using this cohort will examine the consistency
of the reported results against formal diagnostic criteria. Also,
while this study observed a signiﬁcant association between
olfactory D and cognitive decline, it did not examine the
underlying mechanisms involvedin such a distinctiveeffectfor
odordifferentiationascomparedwithotherolfactoryfunctions.
In conclusion, the association between the olfactory
function and ongoing cognitive decline established in this
study provides further evidence in support of the inclusion of a
smell assessment alongside other neuropsychological mea-
sures in standard health screens for older adults. Many
studieshavereportedolfactoryimpairmentsbothinpreclinical
and clinical phases of AD. However, as noted by us and
others, the predictive value of olfactory assessment in
screening those at a higher risk for AD needs further
research
91,92 to improve its sensitivity and speciﬁcity.
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